Application of cyclosporine A in myelodysplastic syndrome--review.
- Author:
Mei GUAN
1
Author Information
1. Department of Hematology, Peking Union Hospital, Beijing 100730, China. Lennon007@sina.com
- Publication Type:Journal Article
- MeSH:
Cyclosporine;
adverse effects;
therapeutic use;
Humans;
Immunosuppressive Agents;
therapeutic use;
Myelodysplastic Syndromes;
drug therapy;
immunology
- From:
Journal of Experimental Hematology
2003;11(6):678-680
- CountryChina
- Language:Chinese
-
Abstract:
Treatment of myelodysplastic syndrome (MDS) remains unsatisfactory. It is possible that immunosuppressive therapy might be effective for a certain subset of patients with MDS. In this review 105 patients with MDS who were treated with cyclosporin A (CsA) including 90 RA, 5 RARS, 10 RAEB, were analyzed. The dose of CsA was 2 - 12 mg/(kg x d) for at least three months. Hematological improvement was observed in 64 patients (61%), and complete remission was observed in 14 patients (13.3%). These results indicated that CsA immunosuppressive therapy may be useful for IPSS low, intermediate-1 and intermediate-2 MDS patients.
